261 related articles for article (PubMed ID: 28472509)
21. A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis.
Mohile NA; Forsyth P; Stewart D; Raizer JJ; Paleologos N; Kewalramani T; Louis DN; Cairncross JG; Abrey LE
J Neurooncol; 2008 Sep; 89(2):187-93. PubMed ID: 18458821
[TBL] [Abstract][Full Text] [Related]
22. Clinical discussion of the management of anaplastic oligodendroglioma/oligoastrocytoma (both codeleted and nondeleted).
Anderson MD; Gilbert MR
J Natl Compr Canc Netw; 2014 May; 12(5):665-72. PubMed ID: 24812135
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.
Chinot OL; Honore S; Dufour H; Barrie M; Figarella-Branger D; Muracciole X; Braguer D; Martin PM; Grisoli F
J Clin Oncol; 2001 May; 19(9):2449-55. PubMed ID: 11331324
[TBL] [Abstract][Full Text] [Related]
24. Low-grade and anaplastic oligodendroglioma.
Van Den Bent MJ; Bromberg JE; Buckner J
Handb Clin Neurol; 2016; 134():361-80. PubMed ID: 26948366
[TBL] [Abstract][Full Text] [Related]
25. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.
Wick W; Roth P; Hartmann C; Hau P; Nakamura M; Stockhammer F; Sabel MC; Wick A; Koeppen S; Ketter R; Vajkoczy P; Eyupoglu I; Kalff R; Pietsch T; Happold C; Galldiks N; Schmidt-Graf F; Bamberg M; Reifenberger G; Platten M; von Deimling A; Meisner C; Wiestler B; Weller M;
Neuro Oncol; 2016 Nov; 18(11):1529-1537. PubMed ID: 27370396
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
van den Bent MJ; Brandes AA; Taphoorn MJ; Kros JM; Kouwenhoven MC; Delattre JY; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Enting RH; French PJ; Dinjens WN; Vecht CJ; Allgeier A; Lacombe D; Gorlia T; Hoang-Xuan K
J Clin Oncol; 2013 Jan; 31(3):344-50. PubMed ID: 23071237
[TBL] [Abstract][Full Text] [Related]
27. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T
Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
Wahl M; Phillips JJ; Molinaro AM; Lin Y; Perry A; Haas-Kogan DA; Costello JF; Dayal M; Butowski N; Clarke JL; Prados M; Nelson S; Berger MS; Chang SM
Neuro Oncol; 2017 Feb; 19(2):242-251. PubMed ID: 27571885
[TBL] [Abstract][Full Text] [Related]
29. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
Cairncross G; Wang M; Shaw E; Jenkins R; Brachman D; Buckner J; Fink K; Souhami L; Laperriere N; Curran W; Mehta M
J Clin Oncol; 2013 Jan; 31(3):337-43. PubMed ID: 23071247
[TBL] [Abstract][Full Text] [Related]
30. CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design.
Jaeckle KA; Ballman KV; van den Bent M; Giannini C; Galanis E; Brown PD; Jenkins RB; Cairncross JG; Wick W; Weller M; Aldape KD; Dixon JG; Anderson SK; Cerhan JH; Wefel JS; Klein M; Grossman SA; Schiff D; Raizer JJ; Dhermain F; Nordstrom DG; Flynn PJ; Vogelbaum MA
Neuro Oncol; 2021 Mar; 23(3):457-467. PubMed ID: 32678879
[TBL] [Abstract][Full Text] [Related]
31. Initial treatment patterns over time for anaplastic oligodendroglial tumors.
Panageas KS; Iwamoto FM; Cloughesy TF; Aldape KD; Rivera AL; Eichler AF; Louis DN; Paleologos NA; Fisher BJ; Ashby LS; Cairncross JG; Roldán Urgoiti GB; Wen PY; Ligon KL; Schiff D; Robins HI; Rocque BG; Chamberlain MC; Mason WP; Weaver SA; Green RM; Kamar FG; Abrey LE; Deangelis LM; Jhanwar SC; Rosenblum MK; Lassman AB
Neuro Oncol; 2012 Jun; 14(6):761-7. PubMed ID: 22661585
[TBL] [Abstract][Full Text] [Related]
32. Treatment recommendations for anaplastic oligodendrogliomas that are codeleted.
Anderson MD; Gilbert MR
Oncology (Williston Park); 2013 Apr; 27(4):315-20, 322. PubMed ID: 23781695
[TBL] [Abstract][Full Text] [Related]
33. Survival outcome and prognostic factors in anaplastic oligodendroglioma: a single-institution study of 95 cases.
Shin DW; Lee S; Song SW; Cho YH; Hong SH; Kim JH; Kim HS; Park JE; Nam SJ; Kim YH
Sci Rep; 2020 Nov; 10(1):20162. PubMed ID: 33214617
[TBL] [Abstract][Full Text] [Related]
34. Spinal cord anaplastic oligodendroglioma with 1p deletion: report of a relapsing case treated with temozolomide.
Wang F; Qiao G; Lou X
J Neurooncol; 2011 Aug; 104(1):387-94. PubMed ID: 21190059
[TBL] [Abstract][Full Text] [Related]
35. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402.
Giannini C; Burger PC; Berkey BA; Cairncross JG; Jenkins RB; Mehta M; Curran WJ; Aldape K
Brain Pathol; 2008 Jul; 18(3):360-9. PubMed ID: 18371182
[TBL] [Abstract][Full Text] [Related]
36. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
Kouwenhoven MC; Gorlia T; Kros JM; Ibdaih A; Brandes AA; Bromberg JE; Mokhtari K; van Duinen SG; Teepen JL; Wesseling P; Vandenbos F; Grisold W; Sipos L; Mirimanoff R; Vecht CJ; Allgeier A; Lacombe D; van den Bent MJ
Neuro Oncol; 2009 Dec; 11(6):737-46. PubMed ID: 19224764
[TBL] [Abstract][Full Text] [Related]
37. Rise of oligodendroglioma hypermutator phenotype from a subclone harboring TP53 mutation after TMZ treatment.
Higuchi F; Uzuka T; Matsuda H; Sumi T; Iwata K; Namatame T; Shin M; Akutsu H; Ueki K
Brain Tumor Pathol; 2024 Apr; 41(2):80-84. PubMed ID: 38294664
[TBL] [Abstract][Full Text] [Related]
38. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
; Cairncross G; Berkey B; Shaw E; Jenkins R; Scheithauer B; Brachman D; Buckner J; Fink K; Souhami L; Laperierre N; Mehta M; Curran W
J Clin Oncol; 2006 Jun; 24(18):2707-14. PubMed ID: 16782910
[TBL] [Abstract][Full Text] [Related]
39. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
40. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression.
Levin N; Lavon I; Zelikovitsh B; Fuchs D; Bokstein F; Fellig Y; Siegal T
Cancer; 2006 Apr; 106(8):1759-65. PubMed ID: 16541434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
